ImmunityBio (IBRX) News
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IBRX news summary
We found 46 recent headlines mentioning ImmunityBio (IBRX): 0 in the past week and 14 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. IBRX is making an outsized move today, down 8.37% at $6.02, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ImmunityBio headlines
- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.NasdaqIBRX, HALO, TGTX, AMRX
- Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?Key PointsImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate.Nasdaq
- ImmunityBio, Inc. Reports Q3 2026 Net Product Revenue of $48.7 Million and FDA Label Expansion for ANKTIVAImmunityBio, Inc. reported its financial results for the third quarter ended September 30, 2026, with net product revenue reaching $48.7 million, representing a 53% increase year-over-year. For the…Nasdaq
- ImmunityBio, Inc. Announces ANKTIVA Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 TrialImmunityBio, Inc. announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005, a randomized, controlled, registrational trial evaluating intravesical ANKTIVA…Nasdaq
- ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of -25.00% and -19.60%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqIBRX, BHST
- ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 MillionCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial…Business Wire
- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownAGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.NasdaqAGEN, TGTX, AMRX, IBRX
- SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineSarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.NasdaqSRPT, AMRX, IBRX
- ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock UpZoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.NasdaqZTS, TGTX, AMRX, IBRX
- Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/YVTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.NasdaqVTRS, TGTX, AMRX, IBRX
- AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedAmneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.NasdaqAMRX, TGTX, IOVA, IBRX
- NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook RaisedNovo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.NasdaqNVO, TGTX, IOVA, IBRX
- Insmed (INSM) Reports Q3 Loss, Tops Revenue EstimatesInsmed (INSM) delivered earnings and revenue surprises of -35.29% and +4.62%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqINSM, IBRX
- Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…NasdaqIBRX, PRME
- Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?Here is how HeartSciences Inc. (HSCS) and ImmunityBio (IBRX) have performed compared to their sector so far this year.NasdaqHSCS, IBRX
- ImmunityBio: Not Executing At The Level That The Market Is Pricing InSeeking Alpha
- ImmunityBio: Jury May Still Be Out On Anktiva Despite Latest NMIBC WinSeeking Alpha
- FDA Expands ImmunityBio's Anktiva Label in Bladder CancerIBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.NasdaqIBRX, AMRN, CORT
- Wednesday's ETF with Unusual Volume: HYPThe Golden Eagle Dynamic Hypergrowth ETF is seeing unusually high volume in afternoon trading Wednesday, with over 414,000 shares traded versus three month average volume of about 29,000. Shares of…NasdaqHYP, INTC, IBRX, HUT
- ImmunityBio's Anktiva gains expanded bladder cancer approvalSeeking Alpha
- ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.NasdaqIBRX, PTCT
- Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqQGEN, IBRX
- Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqIBRX, RGEN
- ImmunityBio: None Of The Moonshots Is Priced InSeeking Alpha
- ImmunityBio: ANKTIVA Is Real, The Valuation Isn'tSeeking Alpha
- IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva UptakeImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.NasdaqIBRX, LQDA, HRMY
- ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqIBRX, AGEN
- Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue EstimatesStoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqSTOK, IBRX
- ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)Seeking Alpha
- ImmunityBio: ANKTIVA's Commercial Momentum Supports A BuySeeking Alpha
- ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A HoldSeeking Alpha
- ImmunityBio: A Long-Term Bull Case Worth WatchingSeeking Alpha
- ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price…NasdaqIBRX, ACIU
- IBRX and the BCG Shortage: Deals That Could Expand DemandImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.NasdaqMRK, URGN, IBRX
- IBRX Stock Outlook After Q1 Results and a New FDA ReviewImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.NasdaqAGEN, IOVA, IBRX
- ImmunityBio: Anktiva Explained and What Comes NextIBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.NasdaqAGEN, IOVA, IBRX
- ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar BreakoutSeeking Alpha
- Why ImmunityBio Stock is Soaring Higher TodayKey PointsImmunityBio's bladder cancer treatment could soon gain approval for use in many new cases.Nasdaq
- FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer TherapyImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.NasdaqIMCR, IBRX, INDV
- ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder CancerIBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.NasdaqIMCR, IBRX, INDV
- ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAMSeeking Alpha
- Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond AnktivaSeeking Alpha
- ImmunityBio: No Need To Rush Into Buying Today - Why I'm Downgrading To HoldSeeking Alpha
- ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On ExpansionSeeking Alpha
- ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call TranscriptSeeking Alpha
- ImmunityBio: Disconnect Between Clinical Progress And Stock PerformanceSeeking Alpha